

Monash Investors Small Companies Trust

Hedge Fund (ASX : MAAT)



High Conviction
Fund



Australian Small
Companies



Proven Track
Record¹



Buy and Sell on
the ASX or direct

January 2024 Fund Update

The market continued to rise in January with the Fund up 0.2% after fees compared to the S&P/ASX Small Ords up 0.9% for the month.

Performance has been quite volatile over the last three months but overall we have seen strong returns, with the Fund up 13.9% and the S&P/ASX Small Ords up 15.8%.

Once again our Uranium exposures Boss Energy and Paladin (ASX: BOE and PDN) were good contributors. Both of these companies have large reserves in good jurisdictions, strong management expertise and are low risk plays on the commodity. The prospects for uranium supply and demand remain highly favourable. Since the end of January the price of Uranium remains around its recent highs, over \$100/lb more than double the price it has trade over the previous 12mths.

Telix (ASX: TLX) continues to its seemingly inexorable progress and share price rerating. Telix is strongly growing its radiopharmaceutical sales and has a pipeline of new drugs to come. We regularly shave the portfolio weight in Telix as it rises in order to control its effect on the portfolio when its share price encounters volatility. We can easily justify the current pricing of TLX based on its two existing commercial products (the kidney imaging product will commercialise this calendar year). Therefore the market is placing zero value on its highly prospective pipeline.

Pleasingly a newer holding, Austin Engineering (ASX: ANG) upgraded its guidance in January ahead of its first half result to come in February. Austin makes replacement truck trays and buckets for mining companies. It's now

Return Summary¹ (after all fees)

1 Month	3 Months
+0.2%	+13.9%
1 Year	Since Inception
-1.8%	-1.2% _{pa}



Our Investment team: Sebastian Correia, Simon Shields and Shane Fitzgerald

This fund is appropriate for investors with "High" and "Very High" risk and return profiles. A suitable investor for this fund is prepared to accept high risk in the pursuit of capital growth with a medium to long investment timeframe. Investors should refer to the [TMD](#) for further information.

¹ Inception date is 28 May 2021. Past performance is not indicative of future performance.

Monash Investors Small Companies Trust

Hedge Fund (ASX : MAAT)

delivering scale economies as it grows its volumes which is resulting in significantly expanding margins.

Impedimed (ASX: IPD) was a significant detractor in January. Following the recent board and management changes there has also been significant turnover in the shareholder base. Nevertheless, the company is on track to become the standard of care to monitor cancer patients for lymphedema, and is adequately capitalized to do so.

February is the half year reporting month. We have conviction in the upside pay-offs expected from our holdings, and a particularly strong conviction that the portfolio will do well as a whole, going into reporting season.

Looking at the portfolio as a whole

Monash Investors aims to identify businesses which are likely to undergo step-changes in their business prospects which will lead to material share price movements. We draw upon our experience in order to exploit recurring business situations and patterns of behaviour, to identify and invest in a portfolio of compelling opportunities.

The Fund's major exposures continue to be to Healthcare, Consumer Discretionary, IT, Energy (via Uranium), and Mining Services.

Return Summary Since Inception (after fees) ²		
	MAAT	Small Ords
CYTD	0.17%	0.90%
FYTD	0.97%	7.37%
1 month	0.17%	0.90%
3 Month	13.87%	15.80%
6 Month	0.42%	3.70%
1 Year	-1.77%	2.10%
2 Years pa	-2.79%	-1.22%
Since Inception pa	-1.23%	-1.31%

Return Summary Since Inception (after fees) ²		
	MAIF	Small Ords
CYTD	0.25%	0.90%
FYTD	1.19%	7.37%
1 month	0.25%	0.90%
3 Month	13.00%	15.80%
6 Month	0.61%	3.70%
1 Year	-1.20%	2.10%
2 Years pa	-2.35%	-1.22%
3 Years pa	0.59%	1.33%
4 Years pa	6.44%	2.33%
5 Years pa	11.15%	5.44%
7 Years pa	8.47%	6.42%
Since Inception pa	9.29%	5.96%

²Due to lack of MAAT history, data from Monash Small Companies Fund (MAIF) (inception date 2 July 2012) has been used. Glossary of terms can be found on the Fund's website at www.monashinvestors.com/glossary/

Monash Investors Small Companies Trust

Hedge Fund (ASX : MAAT)

For MAAT Unit Registry enquiries, please contact

Apex Fund Services Pty Limited
P: 1300 133 451 (in Australia)
+61 2 8259 8888 (international)
E: registry@apexgroup.com

For all business development enquiries, please contact

Cameron Harris
P: +61 400 248 435
cameron@gsmcapital.com.au

For more information about MAAT and the strategy, please refer to the Monash Investors website at www.monashinvestors.com. You can also [follow us on Livewire here](#) or [subscribe to our updates here](#)

This document is prepared by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL 337 927 ("Sanlam") for the provision of general financial product advice in relation to the Monash Investors Small Companies Trust (Hedge Fund) ARSN 642 280 331 ("Fund") and authorised for release by The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") as the responsible entity of, and issuer of units in the Fund. Monash Investors is the investment manager of the Fund. A Product Disclosure Statement ("PDS") dated 17 July 2023 together with a Target Market Determination ("TMD"), both issued by Perpetual, is available for the Fund at www.monashinvestors.com. You should obtain and consider the PDS and TMD for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. The information provided is general information only and is not intended to provide you with financial advice, it does not consider your investment objectives, financial situation or particular needs. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. No company in Perpetual Group (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of any fund or the return of an investor's capital.

You should not base an investment decision simply on past performance. Past performance is not a reliable indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall. Total returns shown have been calculated using NAV prices after taking into account all ongoing fees and assuming reinvestment of distribution. No allowance has been made for taxation. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Reference to Target Distributions, is a target return only. There is no guarantee the Fund will meet its investment objective. The payment of a quarterly distribution is a goal of the Fund only and neither Monash Investors or Perpetual provide any representations or warranty (whether express or implied) in relation to the payment of any quarterly cash income. The Fund reserves the discretion to amend its distribution policy.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.